Home / Psoriasis / A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China (ADAPT)

A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China (ADAPT)

  Purpose

The objective of this non-interventional, observational study is to assess the effectiveness and patient reported outcome of adalimumab in patients with moderate to severe psoriasis in real world clinical practice in China.

Condition
Psoriasis

Study Type: Observational
Study Design:Observational Model: Cohort
Time Perspective: Prospective
Official Title:Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:

  • Proportion of patients achieving at least a 75% reduction in Psoriasis Area Severity Index (PASI) relative to the baseline PASI score [ Time Frame: At Week 12 ]
    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.

Secondary Outcome Measures:

  • Change from Baseline in Dermatology Life Quality Index (DLQI) [ Time Frame: From Week 0 to Week 12 ]
    The DLQI is a self administered short, simple and practical dermatology-specific quality of life (QoL) questionnaire.

Estimated Enrollment:310
Actual Study Start Date:September 8, 2017
Estimated Study Completion Date:September 30, 2019
Estimated Primary Completion Date:September 30, 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts
Participants with moderate to severe plaque psoriasis in China

Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.

About

Check Also

FDA Accepts Ortho Dermatologic’s NDA for Novel Plaque Psoriasis Treatment, IDP-118

The US Food and Drug Administration has accepted Ortho Dermatologic’s New Drug Application (NDA) for IDP-118 (halobetasol …

Leave a Reply

Your email address will not be published. Required fields are marked *